Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Armandi

Showing results (21-30 of 122) with videos related to

Pageof 13
Sort By:
Frontiers in Endocrinology|December 3, 2021
The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative ReviewAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Nature Reviews. Gastroenterology & Hepatology|January 4, 2026
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews. Gastroenterology & Hepatology|March 7, 2025
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews. Gastroenterology & Hepatology|August 27, 2025
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
United European Gastroenterology Journal|July 21, 2021
Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in GermanyChristian Labenz, Karel Kostev, Angelo Armandi, et al.
Minerva Gastroenterology|July 18, 2020
Elastography for characterization of focal liver lesions: current evidence and future perspectivesCarolina Martelletti, Angelo Armandi, Gian Paolo Caviglia, et al.
Minerva Gastroenterology|April 19, 2021
Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratificationFrancesco Stalla, Angelo Armandi, Chiara Marinoni, et al.
Nutrients|February 11, 2023
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based ProgramsMaria Letizia Petroni, Lucia Brodosi, Angelo Armandi, et al.
Expert Review of Molecular Diagnostics|July 28, 2023
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver diseaseAngelo Armandi, Maurice Michel, Kamela Gjini, et al.
Diagnostics (Basel, Switzerland)|February 2, 2021
Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-AnalysisGian Paolo Caviglia, Angelo Armandi, Chiara Rosso, et al.
Pageof 13

Showing results (21-30 of 122) with videos related to

Sort By:
Pageof 13
Frontiers in Endocrinology|December 3, 2021
The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative ReviewAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Nature Reviews. Gastroenterology & Hepatology|January 4, 2026
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews. Gastroenterology & Hepatology|March 7, 2025
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews. Gastroenterology & Hepatology|August 27, 2025
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
United European Gastroenterology Journal|July 21, 2021
Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in GermanyChristian Labenz, Karel Kostev, Angelo Armandi, et al.
Minerva Gastroenterology|July 18, 2020
Elastography for characterization of focal liver lesions: current evidence and future perspectivesCarolina Martelletti, Angelo Armandi, Gian Paolo Caviglia, et al.
Minerva Gastroenterology|April 19, 2021
Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratificationFrancesco Stalla, Angelo Armandi, Chiara Marinoni, et al.
Nutrients|February 11, 2023
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based ProgramsMaria Letizia Petroni, Lucia Brodosi, Angelo Armandi, et al.
Expert Review of Molecular Diagnostics|July 28, 2023
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver diseaseAngelo Armandi, Maurice Michel, Kamela Gjini, et al.
Diagnostics (Basel, Switzerland)|February 2, 2021
Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-AnalysisGian Paolo Caviglia, Angelo Armandi, Chiara Rosso, et al.
Pageof 13